P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1

• N. W. C. J van de Donk,
• M C Minnema,
• J G Berdeja,
• A Oriol,
• A Krishnan,
• P Rodríguez-Otero,
• E Askari,
• M Mateos,
• L. J Costa,
• R Verona,
• J Ma,
• S Girgis,
• S Yang,
• B. W Hilder,
• J Russell,
• J. D Goldberg,
• A Chari

Affiliations

N. W. C. J van de Donk

1 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam (NL)

M C Minnema

2 University Medical Center Utrecht, Utrecht (NL)

J G Berdeja

3 Sarah Cannon Research Institute and Tennessee Oncology, Nashville (USA)

A Oriol

4 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (ES)

A Krishnan

5 City of Hope Comprehensive Cancer Center, Duarte (USA)

P Rodríguez-Otero

6 Clínica Universidad de Navarra, Navarra (ES)

E Askari

7 Hospital Universitario Fundación Jiménez Díaz, Madrid (ES)

M Mateos

8 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca (ES)

L. J Costa

9 University of Alabama at Birmingham, Birmingham (USA)

R Verona

10 Janssen Research & Development, Spring House (USA)

J Ma

10 Janssen Research & Development, Spring House (USA)

S Girgis

10 Janssen Research & Development, Spring House (USA)

S Yang

10 Janssen Research & Development, Spring House (USA)

B. W Hilder

10 Janssen Research & Development, Spring House (USA)

J Russell

10 Janssen Research & Development, Spring House (USA)

J. D Goldberg

11 Janssen Research & Development, Raritan (USA)

A Chari

12 Mount Sinai School of Medicine, New York (USA)